MeiraGTx Holdings plc Files 8-K
Ticker: MGTX · Form: 8-K · Filed: Dec 9, 2024 · CIK: 1735438
Sentiment: neutral
Topics: regulatory-filing, sec-filing
Related Tickers: MGTX
TL;DR
MeiraGTx filed a routine 8-K on 12/9/24. No major news yet.
AI Summary
MeiraGTx Holdings plc filed an 8-K on December 9, 2024, to report other events and financial statements. The filing does not contain specific details about new events or financial figures within the provided text, but it serves as a standard regulatory update.
Why It Matters
This filing indicates MeiraGTx Holdings plc is fulfilling its regulatory reporting obligations with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report and does not contain information that suggests an immediate change in risk for the company.
Key Players & Entities
- MeiraGTx Holdings plc (company) — Registrant
- 0001558370-24-016089 (other) — Accession Number
- December 9, 2024 (date) — Date of Report
FAQ
What is the purpose of this 8-K filing?
This 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of December 9, 2024.
What is the company's full legal name and jurisdiction of incorporation?
The company's full legal name is MeiraGTx Holdings plc, and it is incorporated in the Cayman Islands.
What is the company's principal executive office address?
The principal executive offices are located at 450 East 29th Street, 14th Floor, New York, NY 10016.
What is the company's telephone number?
The company's telephone number is (646) 860-7985.
What is the SIC code for MeiraGTx Holdings plc?
The Standard Industrial Classification (SIC) code for MeiraGTx Holdings plc is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 474 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-12-09 09:15:16
Key Financial Figures
- $0.00003881 — on which registered Ordinary Shares, $0.00003881 par value per share MGTX The Nasda
Filing Documents
- mgtx-20241209x8k.htm (8-K) — 37KB
- mgtx-20241209xex99d1.htm (EX-99.1) — 24KB
- mgtx-20241209xex99d1001.jpg (GRAPHIC) — 5KB
- 0001558370-24-016089.txt ( ) — 192KB
- mgtx-20241209.xsd (EX-101.SCH) — 3KB
- mgtx-20241209_lab.xml (EX-101.LAB) — 16KB
- mgtx-20241209_pre.xml (EX-101.PRE) — 10KB
- mgtx-20241209x8k_htm.xml (XML) — 5KB
01
Item 8.01 Other Events. On December 9, 2024, MeiraGTx Holdings plc (the "Company") issued a press release announcing that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to AAV2-hAQP1 for the treatment of Grade 2/3 radiation-induced xerostomia (RIX). A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K ("Form 8-K") and is incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release of MeiraGTx Holdings plc, dated December 9, 2024. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 9, 2024 MEIRAGTX HOLDINGS PLC By: /s/ Richard Giroux Name: Richard Giroux Title: Chief Financial Officer and Chief Operating Officer 3